#ESC22: BMS-J&J’s mil­vex­i­an miss­es com­pos­ite end­point, but duo to push drug for­ward with signs of sec­ondary stroke pre­ven­tion and ‘flat bleed­ing curve’

BARCELONA — Bris­tol My­ers Squibb and J&J’s Janssen look to move for­ward with a Phase III of their fac­tor XIa drug in pre­vent­ing sec­ondary stroke de­spite miss­ing the goal­post on a com­pos­ite end­point, the com­pa­nies said Sun­day morn­ing at the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy Con­gress.

Dur­ing the same ses­sion, fac­tor XIa com­peti­tor Bay­er al­so an­nounced it had missed the com­pos­ite end­point in a mid-stage stroke tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER